Patients who have had curative treatment for lung cancer are at an increased risk of developing second primary lung cancers (and other cancers) over the next 10 years. Doctors need to develop better ways of monitoring patients during follow up so we can intervene as quickly as possible with further treatments. Measuring DNA in the blood which has come from the tumour, so called circulating tumour DNA (ctDNA), may be one way to do this.
This is a multi-centre, observational basic science study to follow patient who have undergone radical treatment, surgery or radiotherapy for Non-small Cell Lung Cancer (NSCLC) between two and five years previously. Following consent, participants will be asked to provide blood samples every six months for up to the next five years. Information from their routine clinical care, including information from any imaging, diagnostic tissue samples and blood tests will be collected. We will also request access to any original surplus diagnostic material, as well as future, excess tissue from diagnostic samples. Blood samples will be analysed using various new scientific techniques looking to correlate emergence of new primary cancer (or recurrence of original NSCLC) with blood based markers.
Study Type
OBSERVATIONAL
Enrollment
850
Royal Papworth Hospital
Cambridge, United Kingdom
RECRUITINGRecruitment of 850 patients who have undergone treatment with curative intent for stage 1 - 3A non-small cell lung cancer.
In order to: collect baseline demographics, clinical and past medical history to obtain blood samples every 6 months after recruitment to collect relevant imaging and clinical data as part of their on-going routine clinical care
Time frame: 5 years
To collect blood samples from the cohort of patients.
Have the blood samples been collected at follow up visits.
Time frame: From recruitment through to end of study (or 5 year follow up point, whichever comes first)
To collect surplus diagnostic tissue from the cohort of patients.
To collect surplus diagnostic tissue from original non-small cell lung cancer.
Time frame: Identify original diagnostic sample at recruitment.
To collect surplus diagnostic tissue from new cancer occurrences or relapse from the cohort of patients
Collection of surplus diagnostic tissue if any second primary cancer or recurrence occurs.
Time frame: From recruitment to end of study (or 5 year follow up point, whichever comes first)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.